Novartis

---

General Information

Company Name	Novartis
Year founded	1996
Headquarters	Basel, Switzerland
Number of Locations	140
Key People	Daniel Vasella, CEO and Chairman of the Board of Directors
Net Income	10 267 USD million
Operation Income	11 437 USD million
Revenue	44 267 USD million
Employees	Approximatelly 100 000
website	www.novartis.com

Novartis is one of the world leaders in innovative healthcare products. It was created from the merger between Ciba-Geigy and Sandoz, in 1996. Although its main focus has been developing chemical based pharmaceuticals, throughout the years Novartis has been acquiring several biotechnological companies, therefore expanding the research in the biotechnology field. In 2007, Novartis created a biologics unit, which is divided into three of the four different platforms: Sandoz, Vaccines and Diagnostics and Pharmaceuticals.

---

History

^[1]

• 1758 - Foundation of Geigy
• 1884 – Foundation of Ciba
• 1886 – Foundation of Sandoz
• 1970 – Merge between Ciba and Geigy, creating Ciba-Geigy
• 1996 – Merge between Ciba-Geigy and Sandoz, forming Novartis
• 1996 – 2001
  • Novartis entered the New York Stock Exchange (NYSE)
  • Establishment of the Novartis Institute for Functional Genomics
• 2002 -
  • Investment in Roche Holding AG, with 32% of Roche’s voting shares
  • Acquisition of Lek Pharmaceuticals by Sandoz
  • Creation of the Novartis Institutes for Biomedical Research (NIBR)
• 2003 - Acquisition of a majority interest of Idenix Pharmaceuticals
• 2004 -
  • Opening of the Novartis Institute for Tropical Disease, in Singapore
  • Acquisition of Durasacan A/S and Sabex Holdings Lda., two generic companies
  • Sandoz is named as a division of the Novartis Group
• 2005 -
  • Acquisition of Hexal AG, a leading generics company
  • Acquisition of the North American OTC brand portfolio
  • Acquisition of Chiron Corporation
• 2006 - Creation of a R&D center in Xangai, China
• 2007 - Partnership with Intercell, a biotechnology company

---

Products

^[2]

• Xolair - Monoclonal antibody - novel approach for the treatment of moderate to severe allergic asthma.
• Simulect - Monoclonal antibody for induction therapy in kidney transplantation.
• Ilaris – Monoclonal antibody for interleukin 1-beta blockage, switching off the symptoms of inflammation in CAPS patients.
• Binocrit - (Epoetin alfa) - First glycoprotein biosimilar approved in any highly regulated country, approved for treatment of anemia.

---

Financial Information

^[3]

2009 data of Novartis net sales, R&D spending and number of full-time associates. (*)Corporate data missing.

2009	Net sales (USD million)	R & D spending (USD million)	Full-time associates
Total (*)	44 267	7 307(*)	97 688(*)
Pharmaceuticals	28 538	5 840	56 310
Vaccines and Diagnostics	2 424	508	5 416
Sandoz	7 493	613	23 423
Consumer Health	5 812	346	12 539

---

The BioValley area

Novartis is an integrating part of BioValley, a region located between three countries: Switzerland, France and Germany. This initiative aims to encourage the founding of new companies and the creation of new and innovative jobs in life sciences/biotechnology. This program is co-funded by the German, Swiss and French governements and by the European Union.

---

Cláudia Miranda
66805

---

1. bioinformatics
2. biopharmaceutical
3. company
4. genetic tests
5. monoclonal antibodies
6. nanobiotechnology
7. penicillin; antibiotics
8. pharmaceutical
9. poland
10. portugal
11. product
12. technology
13. tool
14. vaccine

---

1. ^ http://www.novartis.com/about-novartis/company-history/index.shtml
2. ^ http://www.novartis.com/products/index.shtml
3. ^ http://ir2.flife.de/data/novartis2009/igb_html/index.php?bericht_id=1000002&index=1&lang=ENG